As our prior work (12, –, 14) and that of others (15, –, 18) have demonstrated that MEK1/2 inhibitor compounds can provide beneficial effects in murine models of infection and inflammation, we sought to determine whether the MEK1/2 inhibitor compound ATR-002 elicited dual anti-inflammatory and antibacterial effects that may be harnessed to combat cystic fibrosis S. aureus infections. Here, MAP2K1 is linked to cystic fibrosis.